Shares of ImmunoGen Inc. IMGN, +1.42% jumped 12.0% in premarket trading on Monday after the company said the Food and Drug Administration accepted an application for its experimental ovarian-cancer treatment. The mirvetuximab soravtansine monotherapy has a Prescription Drug User Fee Act action date of Nov. 28. ImmuoGen said it is still enrolling patients in a confirmatory trial, with plans to announce data from that study early next year. The company’s stock has declined 51.7% this year, while the broader S&P 500 SPX, +0.01% is down 18.1%.
This article was originally published by Marketwatch.com. Read the original article here.
